Table 1 Clinical and pathologic information
Characteristic | RF+ group (n = 315) | RF− group (n = 388) | P |
|---|---|---|---|
Mean age (y)a | 52.4 ± 12.8 (22–75) | 49.7 ± 12.0 (17–86) | 0.061 |
Sex | |||
Men | 265 (76.7) | 306 (71.5) | 0.076 |
Mean nodule size (mm)a | 33.4 ± 21.6 (8–131) | 36.5 ± 21.7 (7–196) | 0.391 |
Liver backgrounds | |||
HBV infection | 243 (77.1) | ||
Cirrhosis | 218 (69.2) | ||
NAFLD- non cirrhosis | 123 (31.7) | ||
HCV infection- non cirrhosis | 198 (51.0) | ||
Other liver diseases- non cirrhosis | 67 (17.3) | ||
Liver nodules | (w = 328) | (w = 418) | |
Pathologic Analysis | |||
HCC | 206 (62.8) | 204 (48.8) | < 0.001 |
DN/RN | 6 (1.8) | 7 (1.7) | 0.873 |
Focal nodular hyperplasia | 13 (4.0) | 28 (6.7) | 0.104 |
Hemangioma | 15 (4.6) | 25 (6.0) | 0.397 |
ICC | 18 (5.5) | 38 (9.1) | 0.064 |
HCC-ICC | 4 (1.2) | 2 (0.5) | 0.261 |
Biliary adenoma | 3 (0.9) | 4 (1.0) | 0.953 |
Neuroendocrine neoplasm | 8 (2.4) | 12 (2.9) | 0.717 |
Lymphoma | 1 (0.3) | 1 (0.2) | 0.863 |
Angiomyolipoma. | 2 (0.6) | 8 (1.9) | 0.124 |
Inflammatory pseudotumor | 17 (5.2) | 32 (7.7) | 0.176 |
Lipoma | 2 (0.6) | 7 (1.7) | 0.201 |
No pathologic analysis | |||
Follow-up CT or MRI imaging - Hemangioma | 34 (10.4) | 50 (12.0) | 0.494 |